N-sec-butyl-N'-phenylurea | 15054-55-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-sec-butyl-N'-phenylurea
• 英文别名: 1-(sec-butyl)-3-phenylurea；N-sec-Butyl-N'-phenyl-harnstoff；N-sek.-Butyl-N'-phenyl-harnstoff；N-(s-Butyl)-N'-phenylharnstoff；1-Butan-2-yl-3-phenylurea
• CAS: 15054-55-4
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD00208215
• 分子量: 192.261
• InChiKey: VFOWJQYAABAIKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 乙醇 、 silver nitrate 作用下， 生成 N-sec-butyl-N'-phenylurea
  参考文献：
  名称：

  Dixon, Journal of the Chemical Society, 1895, vol. 67, p. 558

  摘要：

  DOI：

文献信息

• α-Haloalkyl Haloformates and Related Compounds 3.¹A Facile Synthesis of Symmetrical and Unsymmetrical Ureas<i>via</i>Chloromethyl Carbamates
  作者：Tamás Patonay、Erzsébet Patonay-Péli、László Zolnai、Ferenc Mogyoródi

  DOI：10.1080/00397919608004663

  日期：1996.11

  Abstract Chloromethyl carbamates were prepared by the reaction of chloromethyl chloroformates with amines and found to produce mono-, symmetrically or unsymmetrically di-and trisubstituted ureas including their N-hydroxy and N-alkoxy derivatives in moderate to good yield.

  摘要 氨基甲酸氯甲酯是通过氯甲酸氯甲酯与胺反应制备的，并发现可以以中等至良好的收率生产单、对称或不对称双和三取代的脲，包括它们的 N-羟基和 N-烷氧基衍生物。
• [EN] C7-SUBSTITUTED CAMPTOTHECIN ANALOGS<br/>[FR] ANALOGUES DE CAMPTOTHÉCINE SUBSTITUÉS EN C7
  申请人：BIONUMERIK PHARMACEUTICALS INC

  公开号：WO2009051580A1

  公开（公告）日：2009-04-23

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B- ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7-修饰紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯的稳定性；(viii) 保持药物的效力；以及(ix) 具有较低的分子量（例如，分子量<600）。
• A Fe₃ O₄ @SiO₂ /Schiff Base/Pd Complex as an Efficient Heterogeneous and Recyclable Nanocatalyst for One-Pot Domino Synthesis of Carbamates and Unsymmetrical Ureas
  作者：Iman Dindarloo Inaloo、Sahar Majnooni

  DOI：10.1002/ejoc.201901140

  日期：2019.10.9

  A palladium‐catalyzed domino method for the direct synthesis of carbamates and ureas has been developed by using readily available and economical starting materials (aryl halide, carbon monoxide, sodium azide, amines, and alcohols) in a one‐pot approach. This efficient and phosgene‐free process provided an inexpensive and attractive route to synthesize the products in good to excellent yields.

  通过一锅法使用容易获得且经济的起始原料（芳基卤化物，一氧化碳，叠氮化钠，胺和醇），已经开发了直接催化氨基甲酸酯和脲合成钯催化的多米诺骨牌方法。这种高效且无光气的工艺提供了一种廉价且诱人的途径，可以以良好的收率获得优良的合成产物。
• A Convenient Method for the Preparation of Primary Amines by the Use of Bisbenzenesulfenimide and Bis-<i>p</i>-chlorophenylsulfenimide
  作者：Teruaki Mukaiyama、Takeo Taguchi、Mineo Nishi

  DOI：10.1246/bcsj.44.2797

  日期：1971.10

  conditions by treating N-substituted bisarylsulfenimides with hydrochloric acid or mercaptan. The N-substituted bisarylsulfenimides were prepared in good yields by the reactions of lithium bisarylsulfenimide with alkyl halides or alkyl p-toluenesulfonates or by the addition reactions of bisarylsulfenimide to olefinic compounds.

  已经建立了一种使用双芳基亚磺酰亚胺制备伯胺的简便方法。通过用盐酸或硫醇处理 N-取代的双芳基亚磺酰亚胺，在温和的反应条件下以良好的收率获得伯胺。N-取代的双芳基亚磺酰亚胺通过双芳基亚磺酰亚胺锂与卤代烷或对甲苯磺酸烷基酯的反应或通过双芳基亚磺酰亚胺与烯烃化合物的加成反应以良好的产率制备。
• Inhibitors of Protein Tyrosine Kinase Activity
  申请人：Mannion Michael

  公开号：US20110098293A1

  公开（公告）日：2011-04-28

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。特别是，本发明涉及抑制生长因子受体的蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号传导。本发明还提供了用于治疗细胞增殖性疾病和状况以及眼科疾病、异常和状况的化合物、组合物和方法。